RRC ID 52089
Author Edeline J, Coulouarn C, Crouzet L, Pracht M, Lepareur N, Clément B, Garin E.
Title Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.
Journal J Vasc Interv Radiol
Abstract 1 denoting antagonism. In HepaRG cells, gemcitabine showed synergy with 90Y (CI = 0.70 [95% confidence interval = 0.65-0.75]), whereas oxaliplatin (CI = 1.15 [1.08-1.21]), paclitaxel (CI = 1.26 [1.15-1.37]), and sorafenib (CI = 1.77 [1.65-1.89]) showed antagonism. In HuCCT1 cells, gemcitabine (CI = 0.54 [0.50-0.58]) and oxaliplatin (CI = 0.86 [0.82-0.90]) showed synergy with 90Y, whereas paclitaxel (CI = 1.18 [1.09-1.27]) and sorafenib (CI = 1.21 [1.12-1.30]) showed antagonism. These results suggest that gemcitabine and oxaliplatin should be tested in combination with 90Y radioembolization for treatment of liver cancer.
Volume 26(12)
Pages 1874-78.e2
Published 2015-12
DOI 10.1016/j.jvir.2015.06.032
PII S1051-0443(15)00647-8
PMID 26596183
MeSH Antineoplastic Agents / administration & dosage Carcinoma, Hepatocellular / pathology Carcinoma, Hepatocellular / therapy* Cell Line, Tumor Cell Survival / drug effects Cell Survival / radiation effects Chemoradiotherapy / methods Cholangiocarcinoma / pathology Cholangiocarcinoma / therapy* Deoxycytidine / administration & dosage Deoxycytidine / analogs & derivatives* Dose-Response Relationship, Drug Dose-Response Relationship, Radiation Drug Synergism Humans Niacinamide / administration & dosage Niacinamide / analogs & derivatives* Organoplatinum Compounds / administration & dosage* Paclitaxel / administration & dosage* Phenylurea Compounds / administration & dosage* Pyridines / administration & dosage* Radiation Tolerance / drug effects Radiopharmaceuticals / administration & dosage Sorafenib Yttrium Radioisotopes / therapeutic use*
IF 2.758
Resource
Human and Animal Cells HuCCT1(RCB1960)